Ageas
Ageas reports on the progress of share buy-back programme
Ageas reports on the progress of share buy-back programme
Further to the initiation of the share buy-back programme announced on 28 August 2024, Ageas reports the purchase of 72,457 Ageas shares in the period from 17-02-2025 until 21-02-2025.
| Date | Number of Shares | Total amount (EUR) | Average price (EUR) | Lowest price (EUR) | Highest price (EUR) |
| 17-02-2025 | 8,958 | 451,133 | 50.36 | 50.10 | 50.60 |
| 18-02-2025 | 16,395 | 828,766 | 50.55 | 50.25 | 50.75 |
| 19-02-2025 | 5,644 | 293,584 | 52.02 | 51.40 | 52.60 |
| 20-02-2025 | 25,000 | 1,280,359 | 51.21 | 51.00 | 52.20 |
| 21-02-2025 | 16,460 | 841,135 | 51.10 | 50.95 | 51.30 |
| Total | 72,457 | 3,694,976 | 51.00 | 50.10 | 52.60 |
Since the start of the share buy-back programme on 16 September 2024, Ageas has bought back 2,117,171 shares for a total amount of EUR 102,042,592. This corresponds to 1.13% of the total shares outstanding.
The overview relating to the share buy-back programme is available on our website.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S9.7.2025 08:41:33 CEST | Press release
Correction to Company Announcement no. 15-2025: Transactions under share buy-back programme
Syensqo SA9.7.2025 08:30:00 CEST | Press release
Syensqo - Participation notification by BlackRock Inc.
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom